JANX PE Ratio & Valuation, Is JANX Overvalued

Historical Valuation

Janux Therapeutics Inc (JANX) is now in the Fair zone, suggesting that its current forward PS ratio of 732.14 is considered Fairly compared with the five-year average of -15.37. The fair price of Janux Therapeutics Inc (JANX) is between 1.56 to 15.40 according to relative valuation method.

Relative Value

Fair Zone

1.56-15.40

Current Price：14.07

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Janux Therapeutics Inc (JANX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Janux Therapeutics Inc (JANX) has a current Price-to-Book (P/B) ratio of 0.84. Compared to its 3-year average P/B ratio of 2.35, the current P/B ratio is approximately -64.25% higher. Relative to its 5-year average P/B ratio of 2.19, the current P/B ratio is about -61.55% higher. Janux Therapeutics Inc (JANX) has a Forward Free Cash Flow (FCF) yield of approximately -8.70%. Compared to its 3-year average FCF yield of -5.91%, the current FCF yield is approximately 47.02% lower. Relative to its 5-year average FCF yield of -5.36%, the current FCF yield is about 62.21% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for JANX competitors is 140.06, providing a benchmark for relative valuation. Janux Therapeutics Inc Corp (JANX.O) exhibits a P/S ratio of 732.14, which is 422.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of JANX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of JANX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is JANX currently overvalued or undervalued?

What is Janux Therapeutics Inc (JANX) fair value?

JANX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Janux Therapeutics Inc (JANX) is between 1.56 to 15.40 according to relative valuation method.

How does JANX's valuation metrics compare to the industry average?

The average P/S ratio for JANX's competitors is 140.06, providing a benchmark for relative valuation. Janux Therapeutics Inc Corp (JANX) exhibits a P/S ratio of 732.14, which is 422.75% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Janux Therapeutics Inc (JANX) as of Mar 11 2026?

As of Mar 11 2026, Janux Therapeutics Inc (JANX) has a P/B ratio of 0.84. This indicates that the market values JANX at 0.84 times its book value.

What is the current FCF Yield for Janux Therapeutics Inc (JANX) as of Mar 11 2026?

As of Mar 11 2026, Janux Therapeutics Inc (JANX) has a FCF Yield of -8.70%. This means that for every dollar of Janux Therapeutics Inc's market capitalization, the company generates -8.70 cents in free cash flow.

What is the current Forward P/E ratio for Janux Therapeutics Inc (JANX) as of Mar 11 2026?

As of Mar 11 2026, Janux Therapeutics Inc (JANX) has a Forward P/E ratio of -4.73. This means the market is willing to pay $-4.73 for every dollar of Janux Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Janux Therapeutics Inc (JANX) as of Mar 11 2026?

As of Mar 11 2026, Janux Therapeutics Inc (JANX) has a Forward P/S ratio of 732.14. This means the market is valuing JANX at $732.14 for every dollar of expected revenue over the next 12 months.

JANX Valuation